Latest Period
Q2 2026
Security Snapshot
Tango Therapeutics, Inc. - Common stock, par value $0.001 per share (TNGX) Institutional Ownership
CUSIP: 87583X109
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
245
Shares (Excl. Options)
213,823,747
Price
$31.26
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock, par value $0.001 per share
- Symbol
- TNGX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 213,823,747
- Total 13F value
- $6,600,505,236
- Portfolio coverage rank
- 0.01%
- Share change
- +30,700,058
- Value change
- +$1,045,899,767
- Number of holders
- 245
- Shares outstanding
- 162,373,380
- SEC-reported price per share
- $26.65
- Insider filing price
- $26.65
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TNGX - Tango Therapeutics, Inc. - Common stock, par value $0.001 per share is tracked under CUSIP 87583X109.
- 245 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 191 to 245 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,767,380,547 to $6,600,505,236.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 245 institutions filings for Q2 2026.
Security key
87583X109
Latest holder period
Q2 2026
13F holders
245
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
TNGX full holder history
Tango Therapeutics, Inc. SEC filings
Tango Therapeutics, Inc. company facts
Tango Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87583X109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
TNGX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.8% | $498,518,530 | 16,270,187 | Farallon Capital Management, L.L.C. | 30 Jun 2026 | |||
| FARALLON PARTNERS L L C/CA | 10% | $119,266,365 | 13,461,215 | Dapice Joshua J. | 31 Dec 2025 | |||
| RTW INVESTMENTS, LP | 9.3% | $278,248,970 | 13,300,620 | RTW Investments, LP | 31 Mar 2026 | |||
| Farallon Capital Partners, L.P. | 7.8% | -19% | $235,500,687 | +$10,464,247 | 11,257,203 | +4.7% | Dapice Joshua J. | 31 Mar 2026 |
| TCG Crossover GP II, LLC | 7% | -14% | $310,930,645 | -$44,424,017 | 10,147,867 | -13% | TCG Crossover GP II, LLC | 30 Jun 2026 |
| FMR LLC | 6.9% | $207,231,825 | +$206,951,665 | 9,905,919 | +73869% | FMR LLC | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC | 6% | $298,507,222 | 9,742,403 | THE GOLDMAN SACHS GROUP, INC. | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.3% | +26% | $75,107,682 | +$26,758,396 | 8,477,165 | +55% | BlackRock, Inc. | 31 Dec 2025 |
| Third Rock Ventures IV, L.P. | 4.7% | -18% | $74,901,244 | -$17,625,000 | 6,374,574 | -19% | Third Rock Ventures IV, L.P. | 06 Feb 2026 |
| Invus Global Management, LLC | 4% | -35% | $118,346,637 | -$52,472,987 | 5,657,105 | -31% | Raymond Debbane | 31 Mar 2026 |
| Adage Capital Management, L.P. | 3.4% | -62% | $171,584,000 | -$220,898,620 | 5,600,000 | -56% | Adage Capital Management, L.P. | 30 Jun 2026 |
| Woodline Partners LP | 2.5% | -52% | $122,577,373 | -$122,543,025 | 4,000,567 | -50% | Woodline Partners LP | 30 Jun 2026 |
As of 30 Jun 2026, 245 institutional investors reported holding 213,823,747 shares of Tango Therapeutics, Inc. - Common stock, par value $0.001 per share (TNGX). This represents 132% of the company’s total 162,373,380 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
99%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 8.6% | 13,900,620 | +4.5% | 3.7% | $434,533,381 |
| BlackRock, Inc. | 7.7% | 12,438,444 | +42% | 0.01% | $388,825,760 |
| FMR LLC | 7.6% | 12,333,339 | +25% | 0.02% | $385,540,161 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.6% | 12,277,000 | +35% | 2.2% | $383,779,020 |
| Boxer Capital Management, LLC | 6.7% | 10,876,219 | 0% | 26% | $339,990,606 |
| GOLDMAN SACHS GROUP INC | 6.1% | 9,980,620 | +97% | 0.03% | $311,994,191 |
| TCG Crossover Management, LLC | 5.6% | 9,081,201 | -14% | 6.8% | $283,878,343 |
| TRV GP IV, LLC | 3.9% | 6,374,574 | 0% | 47% | $120,181,383 |
| Paradigm Biocapital Advisors LP | 3.9% | 6,357,523 | +59% | 3.7% | $198,736,169 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.9% | 6,348,827 | +614% | 0.02% | $198,465,000 |
| Siren, L.L.C. | 3.8% | 6,179,364 | +9.2% | 3.9% | $193,166,919 |
| STATE STREET CORP | 3.7% | 5,979,806 | +29% | 0.01% | $186,928,736 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 5,957,348 | +15% | 0% | $186,226,699 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.4% | 5,600,000 | -56% | 0.25% | $175,056,000 |
| Jupiter Topco LLC | 3.1% | 5,056,352 | 0% | 0.06% | $157,989,049 |
| Deep Track Capital, LP | 2.6% | 4,200,000 | +53% | 1.9% | $131,292,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.6% | 4,190,611 | +1.1% | 1.4% | $130,998,500 |
| Woodline Partners LP | 2.5% | 4,000,567 | -50% | 0.39% | $125,057,724 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 3,742,791 | +40% | 0.01% | $117,021,411 |
| PERCEPTIVE ADVISORS LLC | 2.1% | 3,377,000 | +318% | 1.6% | $105,565,020 |
| Seven Fleet Capital Management LP | 2% | 3,228,144 | +543% | 16% | $95,660,985 |
| Logos Global Management LP | 1.8% | 2,850,000 | -5% | 3.8% | $89,091,000 |
| Caligan Partners LP | 1.5% | 2,500,103 | +3.8% | 3.8% | $78,153,220 |
| Holocene Advisors, LP | 1.5% | 2,410,939 | -39% | 0.17% | $75,365,953 |
| Commodore Capital LP | 1.4% | 2,250,000 | 4.2% | $70,335,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 213,823,747 | $6,600,505,236 | +$1,045,899,767 | $31.26 | 245 |
| 2026 Q1 | 180,109,181 | $3,767,380,547 | +$250,198,813 | $20.92 | 191 |
| 2025 Q4 | 172,390,699 | $1,527,338,138 | +$294,868,824 | $8.86 | 170 |
| 2025 Q3 | 139,967,069 | $1,175,703,546 | +$109,407,056 | $8.40 | 140 |
| 2025 Q2 | 127,196,008 | $651,244,300 | +$113,427,538 | $5.12 | 114 |
| 2025 Q1 | 107,228,944 | $146,966,295 | -$1,500,604 | $1.37 | 119 |
| 2024 Q4 | 106,381,203 | $328,721,243 | -$120,601,739 | $3.09 | 134 |
| 2024 Q3 | 101,459,260 | $781,203,088 | -$3,564,439 | $7.70 | 119 |
| 2024 Q2 | 98,595,824 | $845,901,469 | +$2,628,498 | $8.58 | 116 |
| 2024 Q1 | 98,377,909 | $781,109,580 | +$30,778,538 | $7.94 | 124 |
| 2023 Q4 | 93,643,916 | $927,104,831 | +$41,143,001 | $9.90 | 118 |
| 2023 Q3 | 88,799,639 | $999,861,944 | +$236,872,193 | $11.26 | 99 |
| 2023 Q2 | 68,320,832 | $226,845,382 | -$7,737,842 | $3.32 | 89 |
| 2023 Q1 | 69,836,747 | $275,851,159 | +$1,770,332 | $3.95 | 91 |
| 2022 Q4 | 68,766,073 | $498,554,976 | +$12,927,727 | $7.25 | 83 |
| 2022 Q3 | 68,157,717 | $246,729,459 | -$12,119,590 | $3.62 | 86 |
| 2022 Q2 | 70,452,006 | $319,137,805 | -$11,072,751 | $4.53 | 76 |
| 2022 Q1 | 69,679,958 | $528,174,476 | +$13,385,662 | $7.58 | 70 |
| 2021 Q4 | 67,775,150 | $740,996,532 | +$24,899,642 | $10.94 | 57 |
| 2021 Q3 | 65,465,348 | $844,863,000 | +$844,863,000 | $12.93 | 45 |